Disclosures

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational activities it sponsors. All authors are expected to disclose any financial relationships with any proprietary entity producing health care goods or services that have occurred within 24 months from the start of or during the production of the work and that are relevant to the author’s content. If an author has such an interest, then they must disclose the name of the commercial interest and nature of the relationship (eg, consultant or grantee). An author who has no such financial relationship must declare that they have nothing to disclose. The intent of this disclosure is not to prevent an author with a significant financial or other relationship from making a presentation, but rather to provide readers with information that they can use to make their own judgments. It remains for the audience to determine whether the author’s interests or relationships may influence the work with regard to exposition or conclusion.

Disclosures of financial relationships

Chapter 1, Molecular concepts in hematology and cellular basis of hematopoiesis
Berthold Göttgens: no competing financial interest. Gabriel Ghiaur: no competing financial interest.

Chapter 2, Consultative hematology 1: hospitalbased and selected outpatient topics

Jennifer R. Green: honoraria: North American Thrombosis Forum, Scripps Health. Board membership: EPIC Hematology Steering Board. Grant funding: Health Resources and Services Administration, Centers for Disease Control and Prevention, Patient Centered Outcomes Research Institute, American Thrombosis and Hemostasis Network. Shannon L. Carpenter: Consultancy: CSL Behring, Kedrion Biopharmaceuticals, HEMA Biologics; Novo Nordisk Pharmaceuticals, Inc; Bayer; Genentech. Membership on board of directors: Hemostasis and Thrombosis Research Society. Grant funding: Shire, CSL Behring.

Chapter 3, Consultative hematology 2: women’s health issues

Leslie Skeith: research funding: CSL Behring. Honoraria: Leo Pharma, Sanofi. Molly Weidner Mandernach: no competing financial interest. Andra H. James: research funding: Coagulant Therapeutices. Consulting: Cerus, Octapharma, Tremeau, Hemosonics, Coagulant Therapeutics.

Chapter 4, Hematopoietic growth factors

Sophie Park: research support: Novartis, Pfizer, Takeda, Sandoz, and BMS for research in myelodysplastic syndromes. Gerald A. Soff: research support: Amgen, Dova/Sobi Pharmaceuticals, and Janssen Scientific Affairs. Advisory boards (in the past 5 years: Amgen, Janssen Scientific Affairs, Bayer Pharmaceuticals, Dova Pharmaceuticals, Bristol Myers Squibb, Pfizer, Novartis, Anthos Therapeutics, and Hengrui (USA) Ltd.

Chapter 5, Iron physiology, iron overload, and the porphyrias

Elizabeta Nemeth: stock ownership: Intrinsic LifeSciences and Silarus Therapeutics. Consultancy: Protagonist Therapeutics, Ionis Pharmaceuticals, Disc Medicine, and Astra- Zeneca-Fibrogen. Carol Mathew: no competing financial interest.

Chapter 6, Acquired underproduction anemias

Jacquelyn M. Powers: research funding to her institution: American Regent. Maria Domenica Cappellini: no competing financial interest.

Chapter 7, Thalassemia, sickle cell disease, and other hemoglobinopathies

Payal Desai: advisory Board: Pfizer, GBT, Takeda, and Forma. Speaker & Research Project: Novartis. Rakhi Naik: Rigel, Elsevier. Jeffrey Lebensburger: consultant: Novartis, Emmaus, Forma Therapeutics, Agios.

Chapter 8, Hemolytic anemias excluding hemoglobinopathies

Kevin H. M. Kuo: consultancy: Agios, Alexion, Apellis, Aruvant, Bioverativ/Sanofi, Bluebirdbio, Celgene/BMS, Forma, Novartis, and Pfizer. Member of the scientific advisory board: Agios. Honoraria: Agios, Alexion. and Novartis. Research support: Pfizer. Scientific collaboration: Abfero and Phoenicia Biosciences. Samuel A. Merrill: member of scientific advisory board: True North Therapeutics, Alexion, and Rigel.

Chapter 9, Thrombosis and thrombophilia

Paul Monagle: no competing financial interest. Bethany Samuelson Bannow: no competing financial interest.

Chapter 10, Bleeding disorders

Sven Olson: no competing financial interest. Riten Kumar: consultancy: Bayer.

Chapter 11, Disorders of platelet number and function

Hanny Al-Samkari: consultancy: Agios, Dova, Argenx, Sobi, and Rigel. Research funding: Amgen, Agios, and Dova. Michele P. Lambert: advisory board membership: Octapharma and Shionogi. Consultancy: Amgen, Novartis, Shionogi, Dova, Principia, Argenx, Rigel, and Bayer. Research funding: Sysmex, Novartis, Rigel, and AstraZeneca.

Chapter 12, Laboratory hematology

Kristi J. Smock: no competing financial interest. Kenneth D. Friedman: consultancy: Instrumentation Laboratory, Siemens, and Takeda.

Chapter 13, Transfusion medicine

Michelle P. Zeller: medical officer with Canadian Blood Services. Honoraria: Pharmacosmos, Pfizer, and American Society of Hematology; research funding: Canadian Institute of Health Research, Canadian Blood Services, and Pfizer Global Medical Grants. Stella T. Chou: consultancy: Platelet- Bio. Honoraria: American Society of Hematology, Wolters Kluwer, and Engage Health Media. Research funding: National Institutes of Health and Hyundai Hope on Wheels.

Chapter 14, Hematopoietic cell transplantation and cellular therapy 

Irum Khan: honoraria: Takeda and Celgene. Nirav N. Shah: honoraria and/or travel support: Incyte, Celgene, Lily, and Miltenyi Biotec. Membership on scientific advisory board: Lilly, Kite, Celgene, Legend, Epizyme, Seattle Genetics, and TG Therapeutics. Equity ownership in: Exelixis and Geron. Institutional research support for clinical trials: Miltenyi Biotec. Matthew Ulrickson: no competing financial interest.

Chapter 15, Myeloid disorders and inherited bone marrow failure syndromes

Boglarka Gyurkocza: clinical trial support: Actinium Pharmaceuticals. Marcin Wlodarski: no competing financial interest. Cynthia E. Dunbar: research and clinical trial support: Novartis.

Chapter 16, Chronic myeloid leukemia

Kendra L. Sweet: research funding: Incyte. Membership on advisory boards: Novartis, Bristol Myers Squibb and Arog. Honorarium: Astellas. Ehab L. Atallah: research funding: Novartis and Takeda. Consultancy: Pfizer, Celgene, Novartis, and Takeda.

Chapter 17, Myeloproliferative neoplasms

Angela Fleischman: membership on advisory board: PharmaEssentia, CTI, and BMS. Kristen Pettit: membership on an advisory board: PharmaEssentia and Kura Oncology.

Chapter 18, Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes

Bhumika J. Patel: speaker bureau: Alexion and Apellis. Catherine Smith: research funding: AbbVie. Clinical trial: Celgene.

Chapter 19, Acute myeloid leukemia

Neerav Shukla: no competing financial interest. Michael F. Walsh: no competing financial interest. Roland B. Walter: laboratory research grants and/or clinical trial support: Amgen, Aptevo, Celgene, ImmunoGen, Janssen, Jazz, MacroGenics, Pfizer, and Selvita. Ownership interest in: Amphivena. Consultancy: Amphivena, Astellas, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Kite, Kronos, and MacroGenics.  

Chapter 20, Acute lymphoblastic leukemia and lymphoblastic lymphoma

Oliver G. Ottmann: research funding: Incyte and Amgen. Liora Schultz: no competing financial interest.

Chapter 21, Hodgkin lymphoma

Celeste Bello: research advisory board (with honorarium): Seattle Genetics. Pamela B. Allen: research advisory board (with honorarium): Bayer, Daichii Sankyo, Imbrium, and Kyowa Kirin. Research funding: Kyowa Kirin.

Chapter 22, Indolent non-Hodgkin lymphomas

Sairah Ahmed: no competing financial interest. David T. Yang: consultancy: Novartis.

Chapter 23, Aggressive non-Hodgkin and Burkitt lymphoma

Allison Rosenthal: no competing financial interest. Amitkumar Mehta: research funding: Incyte, Takeda, Forty Seven Inc/Gilead, Juno Pharmaceuticals/BMS, Celgene/BMS, OncoTartis, Innate Pharmaceuticals, SeaGen, TG Therapeutics, Affimed, Merck, Kite/Gilead, Roche-Genentech, and ADC Therapeutics. Consultancy, speaker, or advisory board member: Gilead, AstraZeneca, Pharmacyclics, SeaGen, Morphosys/Incyte, TG Therapeutics, Kyowa Kirin, and Rigel Pharmaceuticals.

Chapter 24, Chronic lymphocytic leukemia/small lymphocytic lymphoma

Tanya Siddiqi: speaker: Pharmacyclics, AstraZeneca, Bristol Myers Squibb, and Janssen. Advisor: Pharmacyclics, Astra- Zeneca, Bristol Myers Squibb, Juno Therapeutics, Celgene, Kite Pharma, and BeiGene. Jennifer Woyach: consultant: Pharmacyclics, Janssen, AbbVie, AstraZeneca, BeiGene, Arqule, and Loxo.

Chapter 25, Plasma cell disorders

Caitlin Costello: consultancy: BMS, Janssen, Takeda, Karyopharm, and Oncopeptides. Research funding: Celgene, Takeda, Pfizer, and Poseida. Rafael Fonseca: consultancy: Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Karyopharm, Merck, Juno, Kite, Aduro, OncoTracker, Oncopeptides, GSK, and AbbVie. Scientific advisory board member: Adaptive Biotechnologies, Caris Life Sciences, and OncoTracker.

Discussion of off-label drug use

In compliance with ACCME policy, the American Society of Hematology requires all authors to disclose any discussion of off-label drug use in their chapters.

Chapter 1, Molecular concepts in hematology and cellular basis of hematopoiesis

No discussion of off-label drug use.

Chapter 2, Consultative hematology 1: hospital based and selected outpatient topics

Jennifer R. Green and Shannon L. Carpenter: corticosteroids and rituximab for use in TTP; ATIII and activated protein C for DIC; cyclophosphamide, corticosteroids, IVIG, and rituximab for CAPS; corticosteroids, intravenous immunoglobulin, rituximab, and thrombopoietin receptor agonists for pediatric ITP; rituximab for adult ITP and TTP; granulocyte-stimulating factor outside of severe congenital neutropenia. Desmopressin for use in platelet function disorders; desmopressin, recombinant FVIIa, prothrombin complex concentrate, activated prothrombin complex concentrate, fibrin glue, ε-aminocaproic acid, and tranexamic acid for use in surgical bleeding and reversal of direct oral anticoagulants; IVIG for posttransfusion purpura; IVIG for drug-induced ITP; conjugated estrogens for use in uremic bleeding; hemoglobin-based oxygen carriers for anemia in patients who refuse blood products.

Chapter 3, Consultative hematology 2: women’s health issues

Almost all medications are considered off-label in pregnancy.

Chapter 4, Hematopoietic growth factors

Sophie Park: deferasirox and lenalidomide in myelodysplastic syndromes. Gerald A. Soff: all discussion of thrombopoietin- related drugs is currently off-label.

Chapter 5, Iron physiology, iron overload, and the porphyrias

Off-label use of iron chelation therapy.

Chapter 6, Acquired underproduction anemias No discussion of off-label drug use.

Chapter 7, Thalassemia, sickle cell disease, and other hemoglobinopathies

No discussion of off-label drug use.

Chapter 8, Hemolytic anemias excluding hemoglobinopathies

Azathioprine, bortezomib, chlorambucil, cyclophosphamide, cyclosporine, danazol, eculizumab, erythropoietin, IV immunoglobulin, mycophenolate mofetil, and rituximab in the treatment of autoimmune hemolytic anemia. xxiv Disclosures Sutimlimab in the treatment of cold agglutinin disease. Eculizumab in the treatment of Shiga toxin–mediated thrombotic microangiopathy (TMA) and drug-induced TMA. Eculizumab in the treatment of drug-induced thrombotic microangiopathy.

Chapter 9, Thrombosis and thrombophilia

No discussion of off-label drug use.

Chapter 10, Bleeding disorders

Recombinant factor VIIa for management of bleeding in hemophilia at doses and regimens that are not approved and for other off-label indications, antifibrinolytics for bleeding of unknown cause, and prothrombin complex concentrates for treatment of factor II and X deficiency.

Chapter 11, Disorders of platelet number and function

Desmopressin for inherited platelet function defects and uremic platelets; recombinant factor VIIa for inherited platelet function defects; rituximab for immune thrombocytopenia and thrombotic thrombocytopenic purpura; fondaparinux, bivalirudin, and direct oral anticoagulants for heparin-induced thrombocytopenia.

Chapter 12, Laboratory hematology

No discussion of off-label drug use.

Chapter 13, Transfusion medicine

No discussion of off-label drug use.

Chapter 14, Hematopoietic cell transplantation and cellular therapy

Drug and cellular therapy for hematologic malignancies and hematopoietic cell transplantation.

Chapter 15, Myeloid disorders and inherited bone marrow failure syndromes

Androgens (oxymetholone or danazol) in Fanconi anemia and telomeropathies; granulocyte colony-stimulating factor in non-SCN neutropenia; glucocorticoids in Diamond-Blackfan anemia, autoimmune neutropenias, and histiocytic syndromes; iron chelating agents in congenital dyserythropoietic anemias; interferon-γ in congenital dyserythropoietic anemia type I and Erdheim- Chester disease; plerixafor in WHIM syndrome; intravenous immunoglobin in autoimmune neutropenias; interferon-γ in chronic granulomatous disease; colchicine in familial Mediterranean fever; etoposide, methotrexate, cyclosporine, antithymocyte globulin and dexamethasone in hemophagocytic lymphohistiocytosis; topical steroids, nitrogen mustard, and psoralen in Langerhans cell histiocytosis; vinblastine, methotrexate, and glucocorticoids in Langerhans cell histiocytosis.

Chapter 16, Chronic myeloid leukemia

No discussion of off-label drug use.

Chapter 17, Myeloproliferative neoplasms

Interferon for myeloproliferative neoplasms.

Chapter 18, Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal

hemoglobinuria, and myelodysplastic syndromes Bhumika J. Patel: cyclosporine, rabbit antithymocyte globulin, alemtuzumab, and cyclophosphamide. Catherine Smith: deferoxamine, deferasirox, deferiprone, epoetin, darbepoetin, filgrastim, tbo-filgrastim, sargramostim, molgramostim, pegfilgrastim, romiplostim, eltrombopag, clofarabine, and venetoclax.

Chapter 19, Acute myeloid leukemia No discussion of off-label drug use.

Chapter 20, Acute lymphoblastic leukemia and lymphoblastic lymphoma

Blinatumomab, dasatinib, ponatinib, ruxolitinib, bortezomib, venetoclax, navitoclax, and tisagenlecleucel.

Chapter 21, Hodgkin lymphoma

Rituximab for the treatment of lymphocyte-predominant Hodgkin lymphoma; histone deacetylase inhibitors and lenalidomide in relapsed/refractory Hodgkin lymphoma.

Chapter 22, Indolent non-Hodgkin lymphomas

Lenalidomide in follicular lymphoma; rituximab in hairy cell leukemia; bendamustine, brentuximab vedotin, gemcitabine, ibrutinib, and lenalidomide in DLBCL; ibrutinib, and lenalidomide in primary central nervous system lymphoma; alemtuzumab, gemcitabine, lenalidomide, and liposomal doxorubicin in PTCL; mogamulizumab in adult T-cell leukemia/lymphoma.

Chapter 23, Aggressive non-Hodgkin and Burkitt lymphoma

Venetoclax in mantle cell lymphoma; mogamolizumab in adult T-cell leukemia/lymphoma; ibrutinib, lenalidomide, Disclosures xxv mosenutuzumab, glofitamab, and epcoritomab in relapsed/ refractory (R/R) diffuse large B-cell lymphoma; and lenalidomide, ibrutinib, pomalidomide, and PD-1 inhibitors in R/R central nervous system lymphoma.

Chapter 24, Chronic lymphocytic leukemia/small lymphocytic lymphoma

Chimeric antigen receptor T cells.

Chapter 25, Plasma cell disorders

Melphalan has no FDA approval for the treatment of myeloma. Venetoclax is not approved for the treatment of myeloma. Proteasome inhibitors are not approved for maintenance therapy for myeloma. The combination of carfilzomib with alkylators is not FDA approved. Isatuximab is not approved in combination with immunomodulatory drugs for myeloma.